Zevra Therapeutics, Inc. ZVRA R2K

Healthcare · Biotechnology · United States

https://www.zevra.com

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Market & Price

Market Cap

$685.14M

Current Price

$11.59

High / Low (52W)

$12.79 / $7.23

Beta

0.88

Valuation

Stock P/E

5.77

Industry PE

23.65

Forward P/E

6.05

PEG Ratio

10.67

Book Value

$2.72

Price to Book

4.26

P/S

5.60

EV/EBITDA

38.14

Dividend Yield

Profitability & Returns

ROCE

38.56%

ROE

100.65%

ROA

2.76%

Profit Margin

Op Margin

24.38%

EPS (Latest Qtr)

$0.60

EPS (TTM)

$2.01

Balance Sheet & Liquidity

Debt/Equity

0.56

Quick Ratio

4.74

Current Ratio

4.89

Debt

$1.15M

Total Assets

$284.73M

Current Assets

$223.01M

Working Capital

$183.73M

Ownership

Promoter Holding

1.40%

Chg in Prom Hold

FII / Inst Holding

70.73%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$485.67M

Total Revenue (TTM)

$122.29M

EBITDA

$12.73M

Free Cash Flow

$25.85M

Operating Cash Flow

$12.77M

Shares Outstanding

59.12M

Gross Margin

86.07%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

118.82%

Profit 5Y

136.96%

Revenue (YoY)

77.50%

Earnings (YoY)

PROS

Strong return on equity of 100.7%.
Healthy ROCE of 38.6%.
Compounding revenue at 118.8% over 5 years.
Profit CAGR of 137.0% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ZVRA Zevra Therapeutics, Inc. R2K	11.59	5.77	$685.14M	-	38.56%	100.65%	118.82%	136.96%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.40M	25.88M	26.06M	34.12M	36.22M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.34M	12.38M	1.24M	1.52M	1.90M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.06M	13.50M	24.82M	32.60M	34.32M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.42M	25.83M	20.68M	23.29M	25.49M
Operating Income	-4.34M	-7.49M	-3.10M	-5.96M	-6.48M	-7.28M	-6.97M	-9.28M	-10.40M	-10.84M	-7.38M	-8.22M	-9.61M	-8.15M	-14.77M	-13.91M	-17.96M	-11.37M	-7.79M	3.23M	-3.77M	2.59M	-1.21M	6.96M	5.83M	-2.22M	-1.86M	-24.77M	-6.63M	-12.83M	-6.25M	-15.36M	-20.49M	-23.80M	-	-5.36M	-12.33M	4.14M	9.31M	8.83M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.70M	80.57M	1.47M	14.98M	46.88M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.97M	2.01M	2.05M	1.95M	1.71M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.92M	76.91M	-977.00K	12.67M	44.80M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.18M	2.20M	-433.00K	501.00K	6.91M
Net Income	-7.14M	-11.84M	-5.97M	-29.74M	-9.74M	-9.20M	-2.93M	9.77M	-13.41M	-9.94M	-16.32M	-6.52M	-9.98M	-10.57M	-26.22M	-9.99M	-15.07M	-12.29M	-9.26M	3.06M	-5.75M	859.00K	-3.01M	-10.30M	6.20M	-1.76M	-1.86M	-24.04M	-6.62M	-13.22M	-2.57M	-10.37M	-16.62M	-19.93M	-	-3.10M	74.71M	-544.00K	12.16M	37.89M
Diluted EPS	-	-	-2.50	-2.45	-0.68	-0.64	-0.20	-0.58	-0.92	-0.68	-1.11	-0.44	-0.68	-0.72	-	-0.91	-0.94	-	-0.33	0.06	-1.92	0.21	-0.68	-2.49	-0.40	-0.06	-	-	-	-	-	-	-	-0.48	-0.69	-0.06	1.21	-0.01	-	0.60
R&D Expense	3.25M	5.91M	2.12M	2.77M	4.33M	4.72M	3.23M	4.99M	4.29M	7.96M	4.11M	4.65M	6.29M	5.54M	11.64M	10.49M	13.33M	8.53M	4.80M	3.62M	2.13M	1.95M	1.71M	2.27M	2.85M	2.24M	3.08M	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	0	0	0	-	-	-	-	-	-	10.16M	27.46M	23.61M	106.47M
Cost of Revenue	-	-	-	-	-	-	-	-	-	222.00K	2.17M	7.42M	16.48M
Gross Profit	-	-	-	-	-	-	-	-	-	9.94M	25.29M	16.20M	89.99M
Operating Expenses	-	-	-	-	-	-	-	-	-	34.84M	74.89M	103.20M	94.22M
Operating Income	-4.72M	-16.44M	-22.81M	-37.48M	-33.37M	-55.90M	-20.34M	-5.61M	-	-24.90M	-49.60M	-87.00M	-4.23M
EBITDA	-	-	-	-	-	-	-	-	-	-25.53M	-43.54M	-76.40M	98.71M
Interest Expense	-	-	-	-	-	-	-	-	-	335.00K	1.50M	7.35M	7.98M
Pretax Income	-	-	-	-	-	-	-	-	-	-26.80M	-46.05M	-90.14M	86.68M
Tax Provision	-	-	-	-	-	-	-	-	-	-33.00K	0	15.37M	3.45M
Net Income	-5.23M	-24.45M	-54.66M	-16.52M	-43.39M	-56.47M	-24.52M	-12.76M	-	-26.77M	-46.05M	-105.51M	83.23M
Diluted EPS	-	-	-	-	-	-	-	-3.21	-	-1.20	-1.30	-2.28	1.35
R&D Expense	3.37M	11.92M	13.93M	20.47M	20.59M	41.76M	19.41M	8.84M	10.16M	-	-	-	-

Compounded Sales Growth

5 Years:	118.82%
1 Year:	77.50%

Compounded Profit Growth

5 Years:	136.96%
1 Year:	-

Stock Price Performance

1 Year:	+35.56%
6 Months:	+37.98%
3 Months:	+29.79%
1 Month:	+19.86%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Sep 2023	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	13.71M	54.59M	84.89M	52.46M	26.75M	10.51M	11.21M	-	115.34M	-	172.33M	178.13M	284.73M
Current Assets	-	-	-	-	-	-	-	-	-	-	92.83M	-	86.94M	86.03M	223.01M
Cash & Equivalents	2.54M	1.97M	10.26M	32.32M	16.76M	10.87M	18.41M	3.22M	4.21M	-	65.47M	-	43.05M	33.78M	62.41M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	0	1.97M	1.74M
Receivables	-	-	-	-	-	-	-	-	-	-	7.18M	-	16.12M	4.01M	9.88M
Total Liabilities	-	-	38.02M	64.71M	103.58M	109.97M	93.31M	84.96M	77.62M	-	40.22M	-	110.46M	138.46M	130.07M
Current Liabilities	-	-	3.94M	8.34M	6.64M	11.51M	12.00M	5.43M	7.54M	-	12.02M	-	73.72M	34.06M	39.28M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	12.80M	-	5.07M	59.50M	61.93M
Total Debt	-	-	-	-	-	-	-	-	-	-	14.12M	-	43.77M	60.30M	63.21M
Total Equity	-19.18M	-24.27M	-48.51M	-10.12M	-18.70M	-57.52M	-66.57M	-74.46M	-66.41M	-	75.12M	61.52M	61.86M	39.67M	154.66M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	35.45M	-	43.11M	55.25M	58.34M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-20.27M	-29.77M	-33.10M	-54.20M	-23.74M	-1.94M	-	-18.72M	-33.53M	-69.67M	-1.60M
Investing Cash Flow	-	-	-19.14M	-45.85M	27.41M	33.33M	3.23M	-33.00K	-	-36.72M	-17.39M	-22.16M	18.13M
Financing Cash Flow	-	-	61.47M	61.16M	-203.00K	28.02M	4.94M	2.74M	-	8.35M	28.46M	82.11M	12.06M
Capital Expenditure	-51.00K	-47.00K	-135.00K	-643.00K	-181.00K	-21.00K	-26.00K	-33.00K	-102.00K	-93.00K	-296.00K	-	-835.00K
Free Cash Flow	-	-	-20.40M	-30.41M	-33.28M	-54.22M	-23.76M	-1.97M	-	-18.81M	-33.83M	-69.67M	-2.43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-47.08M	-22.46M	-9.72M	28.59M
Share Buybacks	-	-	-	-	-	-	-	0	2.81M	4.72M	3.45M	0	-

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	97.8%	92.1%	68.6%	84.5%
Operating Margin %	-	-	-	-	-	-	-	-	-	-245.1%	-180.6%	-368.5%	-4.0%
Net Margin %	-	-	-	-	-	-	-	-	-	-263.5%	-167.7%	-446.9%	78.2%
ROE %	21.5%	50.4%	540.1%	88.3%	75.4%	84.8%	32.9%	19.2%	-	-35.6%	-74.4%	-266.0%	53.8%
ROCE %	-	-168.1%	-49.3%	-47.9%	-81.5%	-379.2%	-400.7%	-152.7%	-	-24.1%	-50.3%	-60.4%	-1.7%

Shareholding Pattern

Insiders

1.40%

Institutions

70.73%

Public Float

71.74%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Woodline Partners LP	79.98%	3.45M	$40.00M
2	FMR, LLC	74.44%	3.21M	$37.23M
3	Nantahala Capital Management, LLC	58.45%	2.52M	$29.23M
4	Vanguard Capital Management LLC	57.23%	2.47M	$28.62M
5	State Street Corporation	36.19%	1.56M	$18.10M
6	Geode Capital Management, LLC	31.79%	1.37M	$15.90M
7	AIGH Capital Management LLC	27.81%	1.20M	$13.91M
8	Morgan Stanley	27.63%	1.19M	$13.82M
9	Legal & General Group PLC	26.96%	1.16M	$13.48M
10	Blackrock Inc.	-	4.46M	$51.65M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZVRA

No recent headlines available.

ZVRA · Healthcare